Arcadia Biosciences Receives US Patent for Resistant Starch Wheat Technology
-- Non-GM Wheat Offers Potential Health Benefits with Higher Fiber Content and Lower Glycemic Index --
Arcadia’s RS Wheat was developed using the company’s proprietary wheat
genetic diversity library, an extensive and exclusive resource of wheat
lines with high-density variations in genetic composition and gene
function. The RS Wheat project was funded in part by a grant from the
Resistant starch is a form of dietary fiber that is digested more slowly than regular starch. Slower digestion results in a slower release of glucose into the bloodstream, so food products made with RS Wheat have a lower glycemic index. Resistant starch also is fermented in the lower intestine to provide additional colon health benefits.
Compared to conventional wheat varieties, which have very low levels of resistant starch, Arcadia’s RS Wheat has significantly higher levels of total dietary fiber in both whole grain flour and especially refined white flour. Studies have linked resistant starch to improved insulin sensitivity, lower blood glucose levels, and increased satiety, benefitting people with diabetes, pre-diabetes and obesity.
“Because wheat is the world’s largest cultivated crop, it’s a key focus
for the health-promoting benefits of resistant starch,” said
The global market for whole grain and high fiber foods is projected to
The issuance of this key US patent further expands Arcadia’s global patent portfolio, which includes more than 170 patents and patent applications owned or exclusively controlled by Arcadia.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the company's RS Wheat program.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the company’s
and its partners’ and affiliates’ ability to identify and isolate
desired wheat quality traits; the company’s and its partners’ ability to
develop commercial products incorporating the RS Wheat line; the
company’s compliance with laws and regulations that impact the company’s
business, and changes to such laws and regulations; the company’s future
capital requirements and ability to satisfy its capital needs; and the
other risks set forth in the company’s filings with the
Arcadia Biosciences, Inc.
Jeff Bergau, +1-312-217-0419